Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Denmark's ViroGates nine-month revenue jumps 75% on US partner orders

By Reuters News


Overview

  • Denmark medical diagnostics firm's nine-month revenue rose 75%, driven by U.S. partner orders

  • Operating loss narrowed for the period as expenses declined

  • Company maintains 2026 guidance and shifts focus to scalable partnerships


Outlook

  • ViroGates maintains 2026 revenue guidance at DKK 6.5-8 mln and EBIT at DKK -10 to -12 mln

  • Company expects no revenue impact in 2026 from ongoing FDA process for suPARnostic TurbiLatex

  • Decision on IVDR validation for suPARnostic POC+ expected in Q1 2027; approval could take one year


Result Drivers

  • U.S. PARTNER ORDERS - Revenue growth was largely due to its U.S. commercial partner taking delivery of minimum order under 2024 distribution agreement in Q2

  • SLOWER Q3 SALES - Q3 revenue slowed as expected after U.S. partner stocked up in Q2

  • BUSINESS MODEL SHIFT - Shift to larger, scalable partnerships is underway, with new VP of Business Development appointed and partner portfolio under review


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

DKK 6.21 mln

9M Net Loss

DKK 5.68 mln

9M Operating Expenses

-DKK 11.65 mln

9M Operating Profit

-DKK 6.64 mln


Reuters Recommended Reads

  • Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises

  • Nov 5 - Danish biotech firm Genmab's nine-month revenue up on higher royalties and product sales

  • Nov 3 - SOPHiA GENETICS Q3 revenue rises on US market strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.